Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

This study has been completed.
Information provided by:
Regional Hospital Holstebro Identifier:
First received: June 24, 2006
Last updated: May 14, 2008
Last verified: May 2008
We wanted to test the shortterm effects of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.

Condition Intervention Phase
Drug: HMG-CoA reductase inhibition (atorvastatin)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Official Title: Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects.

Resource links provided by NLM:

Further study details as provided by Regional Hospital Holstebro:

Primary Outcome Measures:
  • GFR
  • RPF
  • FEna
  • FELi
  • CLna
  • CLli

Estimated Enrollment: 20
Study Start Date: September 2004
Study Completion Date: February 2005
Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Both men and women
  • Age: Between 20-50
  • BMI<30

Exclusion Criteria:

  • Cl. signs or history of disease of heart, lungs, kidneys or endocrine organs.
  • Abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.ALAT, pl. cholesterol, blood glucose)
  • Albuminuria or glucosuria
  • Cancer
  • Art. hypertension
  • Alcohol abuse
  • Med. treatment, except oral contraceptives
  • Pregnancy or breast feeding
  • Blood donation less than 1 month before study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00345202

Medical research unit, Department of medicin, Holstebro Sygehus
Holstebro, Ringkøbing countie, Denmark, 7500
Sponsors and Collaborators
Regional Hospital Holstebro
Study Chair: Erling B. Pedersen, Professor Holstebro Sygehus
  More Information Identifier: NCT00345202     History of Changes
Other Study ID Numbers: MED.RES.HOS.2004.02.LP 
Study First Received: June 24, 2006
Last Updated: May 14, 2008
Health Authority: Denmark: Ethics Committee

Keywords provided by Regional Hospital Holstebro:
HMG-COA reductase inhibition

Additional relevant MeSH terms:
Atorvastatin Calcium
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on October 21, 2016